Your browser doesn't support javascript.
loading
Cannabinoids for the treatment of autoimmune and inflammatory skin diseases: A systematic review.
Kuzumi, Ai; Yamashita, Takashi; Fukasawa, Takemichi; Yoshizaki-Ogawa, Asako; Sato, Shinichi; Yoshizaki, Ayumi.
Afiliação
  • Kuzumi A; Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
  • Yamashita T; Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
  • Fukasawa T; Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
  • Yoshizaki-Ogawa A; Department of Clinical Cannabinoid Research, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
  • Sato S; Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
  • Yoshizaki A; Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Exp Dermatol ; 33(3): e15064, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38532572
ABSTRACT
In recent years, the medical use of cannabinoids has attracted growing attention worldwide. In particular, anti-inflammatory properties of cannabinoids led to their emergence as potential therapeutic options for autoimmune and inflammatory disorders. Recent studies have also shown that cannabinoid receptors are widely expressed and have endogenous ligands in the skin, suggesting that the skin has its own endocannabinoid system. The aim of this review is to discuss the potential therapeutic effects of cannabinoids in autoimmune and inflammatory skin diseases. Following an overview of cannabinoids and the endocannabinoid system, we describe the cellular and molecular mechanisms of cannabinoids in skin health and disease. We then review the clinical studies of cannabinoids in autoimmune and inflammatory skin diseases including systemic sclerosis (SSc), dermatomyositis (DM), psoriasis (Pso) and atopic dermatitis (AD). A primary literature search was conducted in July 2023, using PubMed and Web of Science. A total of 15 articles were included after excluding reviews, non-human studies and in vitro studies from 389 non-duplicated articles. Available evidence suggests that cannabinoids may be beneficial for SSc, DM, Pso and AD. However, further studies, ideally randomized controlled trials, are needed to further evaluate the use of cannabinoids in autoimmune and inflammatory skin diseases.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Canabinoides Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Canabinoides Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article